Sophie Degroote
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophie Degroote has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Charlotte Vanden Bulcke
Affiliation Department of General Internal Medicine, Ghent University Hospital, Ghent, Belgium
1 shared publication- Cyril Barbezange
Sciensano, Brussels, Belgium
1 shared publication Dirk Vogelaers
Affiliations Department of General Internal Medicine, AZ Delta, Roeselare, Belgium, Department of Physical Medicine and Rehabilitation, Ghent University Hospital, Ghent, Belgium
1 shared publication- Elizaveta Padalko
Ghent University Hospital
1 shared publication - Els Tobback
Department of General Internal Medicine, University Hospital Ghent, Gent, Belgium
1 shared publication - Isabelle Thomas
National Influenza Centre, Sciensano, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
- 5 July 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 628-635
Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
- 5 July 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 628-635
Open AccessEfficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
- Open Access
- 13 January 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (1) , e0262533
Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
Background: The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting.Materials and methods: This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built.Results: Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5–29). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence.Conclusions: Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs.
- 13 January 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (1) , e0262533
Open AccessPatient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
Background: The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting.Materials and methods: This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built.Results: Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5–29). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence.Conclusions: Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs.